These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16708175

  • 1. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M, Ghezzi A, Comi G.
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [Abstract] [Full Text] [Related]

  • 2. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC, Hartung HP.
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [Abstract] [Full Text] [Related]

  • 3. [New therapeutic possibilities for disseminated sclerosis?].
    Wanscher B, Sørensen PS.
    Ugeskr Laeger; 1994 Oct 24; 156(43):6353-8. PubMed ID: 7810008
    [Abstract] [Full Text] [Related]

  • 4. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C, Vukusic S.
    Clin Neurol Neurosurg; 2004 Jun 24; 106(3):263-9. PubMed ID: 15177781
    [Abstract] [Full Text] [Related]

  • 5. Natural history and treatment of multiple sclerosis.
    Weinshenker BG, Sibley WA.
    Curr Opin Neurol Neurosurg; 1992 Apr 24; 5(2):203-11. PubMed ID: 1377973
    [Abstract] [Full Text] [Related]

  • 6. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome.
    Kimiskidis V, Sakellari I, Tsimourtou V, Kapina V, Papagiannopoulos S, Kazis D, Vlaikidis N, Anagnostopoulos A, Fassas A.
    Mult Scler; 2008 Mar 24; 14(2):278-83. PubMed ID: 17942513
    [Abstract] [Full Text] [Related]

  • 7. [Is immunosuppression a future therapeutic strategy for multiple sclerosis?].
    Edan G, Coustans M.
    Pathol Biol (Paris); 2000 Mar 24; 48(2):114-20. PubMed ID: 10815287
    [Abstract] [Full Text] [Related]

  • 8. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y.
    Rinsho Shinkeigaku; 2001 Dec 24; 41(12):1214-7. PubMed ID: 12235841
    [Abstract] [Full Text] [Related]

  • 9. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH.
    Neurology; 1988 Jul 24; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [Abstract] [Full Text] [Related]

  • 10. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S, Hohlfeld R, Voltz R.
    MMW Fortschr Med; 2003 May 26; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH.
    Curr Med Res Opin; 2007 Jun 26; 23(6):1199-208. PubMed ID: 17559719
    [Abstract] [Full Text] [Related]

  • 12. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation].
    Callegaro D, Lana-Peixoto MA, Moreira MA, Marchiori PE, Bacheschi LA, Arruda WO, Campos GB, Lino AM, Melo AS, Rocha FC, Ferreira ML, Ataide L, Maciel DR, Participantes da Reunião do Consenso Expandido sobre Tratamento da Esclerose Múltipla do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla (BCTRIMS).
    Arq Neuropsiquiatr; 2002 Sep 26; 60(3-B):869-74. PubMed ID: 12364965
    [Abstract] [Full Text] [Related]

  • 13. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.
    Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O, Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine.
    Lancet Neurol; 2008 Feb 26; 7(2):173-83. PubMed ID: 18207115
    [Abstract] [Full Text] [Related]

  • 14. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec 26; 16(92):252-7. PubMed ID: 18092425
    [Abstract] [Full Text] [Related]

  • 15. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR.
    J Neurol Sci; 2004 Aug 15; 223(1):41-6. PubMed ID: 15261559
    [Abstract] [Full Text] [Related]

  • 16. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
    Lisak RP.
    Neurology; 1988 Jul 15; 38(7 Suppl 2):5-8. PubMed ID: 3290714
    [Abstract] [Full Text] [Related]

  • 17. [Multiple sclerosis].
    Tanosaki M, Matsunaga M.
    Nihon Rinsho; 2004 May 15; 62 Suppl 5():586-9. PubMed ID: 15197989
    [No Abstract] [Full Text] [Related]

  • 18. [Non-specific immunosuppression and multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 1998 Sep 15; 154(8-9):629-34. PubMed ID: 9809379
    [Abstract] [Full Text] [Related]

  • 19. Treatment of multiple sclerosis in children and adolescents.
    Kuntz NL, Chabas D, Weinstock-Guttman B, Chitnis T, Yeh EA, Krupp L, Ness J, Rodriguez M, Waubant E, Network of US Pediatric Multiple Sclerosis Centers.
    Expert Opin Pharmacother; 2010 Mar 15; 11(4):505-20. PubMed ID: 20163265
    [Abstract] [Full Text] [Related]

  • 20. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L.
    Clin Neurol Neurosurg; 2008 Nov 15; 110(9):878-85. PubMed ID: 18164542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.